This story has been corrected. A previous version erroneously stated that PerkinElmer had $165.5 million cash and cash equivalents at the end of the second quarter last year.
NEW YORK, July 28 (GenomeWeb News) - PerkinElmer Tuesday reported a second-quarter rise in income and revenues, as well as a revenue increase for its life and analytical sciences business.
The company reported income of $20.8 million or $.16 per share compared to $8.4 million or $.07 per share in the second quarter of 2003, while revenues for the quarter totaled $412.6 million, compared to $376.3 million for the year-ago quarter.
Revenues in the life and analytical sciences segment were $257.9 million, versus $246 million for the same period last year.
R&D expenses for the second quarter came to $22.3 million, up slightly from the $21.9 million reported in the same period last year.
As of June 27, the company had $196.7 million in cash and cash equivalents, compared to $165.5 million at the end of the first quarter.